4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $772.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.20M in total
- 9
- 13F holdersQ2 2026, +6 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $772.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FDMT, Q2 2026
No superinvestor reported holding FDMT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by 4D Molecular Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 (view filing)6:43 PM ET | Sep 16 | 6 daysLate | Bizily ScottChief Legal Officer | SSale | −1.64K | $13.65 | −$22.3K | −15.9%8.62K after | 10b5-1 |
| Sep 16, 2026 (view filing)5:13 PM ET | Sep 14 | 2 days | Kirn DavidSee Remarks | SSale | −58.3K | $13.90 | −$811.0K | −7.1%767.5K after | 10b5-1 |
| Sep 3, 2026 (view filing)6:55 PM ET | Sep 1 | 2 days | Bizily ScottChief Legal Officer | SSale | −584 | $14.00 | −$8.18K | −6.3%8.62K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:06 PM ET | Aug 19 | 2 days | Kirn DavidSee Remarks | SSale | −69.1K | $15.75 | −$1.09M | −7.7%825.8K after | 2 lots10b5-1 |
| Aug 17, 2026 (view filing)5:34 PM ET | Aug 13-17 | 4 days | Bizily ScottChief Legal Officer | SSale | −3.27K | $12.10 | −$39.6K | −27.5%8.62K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)4:10 PM ET | Aug 4 | 1 day | Kirn DavidSee Remarks | SSale | −26.8K | $10.23 | −$274.6K | −3.1%844.9K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:45 PM ET | Aug 3 | 1 day | Kirn DavidSee Remarks | SSale | −12.4K | $10.05 | −$124.7K | −1.4%871.7K after | 10b5-1 |
| Jul 14, 2026 (view filing)5:04 PM ET | Jul 9-10 | 5 daysLate | Kirn DavidSee Remarks | SSale | −58.3K | $12.64 | −$737.4K | −6.2%884.2K after | 3 lots10b5-1 |
| Jul 2, 2026 (view filing)4:07 PM ET | Jun 30 | 2 days | Bizily ScottChief Legal Officer | SSale | −6.57K | $14.00 | −$91.9K | −43.2%8.62K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Bizily ScottChief Legal Officer | SSale | −9.81K | $12.00 | −$117.7K | −53.2%8.62K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in 4D Molecular Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 5,746,289 | $76.5M | 0.03% | +5,746,289 | New |
| Ra Capital Management, L.P. | 5,049,779 | $67.2M | 0.58% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,546,059 | $60.5M | 0.00% | +400,756+9.7% | Added |
| Goldman Sachs Group Inc | 4,258,668 | $56.6M | 0.01% | +53,230+1.3% | Added |
| Novo Holdings A/S | 3,249,178 | $43.2M | 2.51% | −401,559−11.0% | Reduced |
| State Street Corp | 2,911,109 | $38.7M | 0.00% | +203,234+7.5% | Added |
| BVF Inc | 2,879,289 | $38.3M | 0.98% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 2,511,887 | $33.4M | 0.02% | +2,511,887 | New |
| Adage Capital Partners GP, L.L.C. | 2,249,203 | $29.9M | 0.04% | +644,047+40.1% | Added |
| Trails Edge Capital Partners, LP | 2,227,917 | $29.6M | 4.70% | +925,000+71.0% | Added |